Trexquant Investment LP I Mab Transaction History

Trexquant Investment LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $366,578 - $1.13 Million	91,416 Added 659.0%	105,288 $422,000
Q2 2022 Aug 11, 2022	BUY	$8.27 - $18.43 $28,986 - $64,597	3,505 Added 33.81%	13,872 $157,000
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $130,002 - $486,523	10,367 New	10,367 $168,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.